Nothing Special   »   [go: up one dir, main page]

Su et al., 2017 - Google Patents

Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile

Su et al., 2017

View HTML
Document ID
662127247651091174
Author
Su S
Ma Z
Hua C
Li W
Lu L
Jiang S
Publication year
Publication venue
Molecules

External Links

Snippet

Peptides derived from the C-terminal heptad repeat (CHR) of human immunodeficiency virus type 1 (HIV-1) envelope protein transmembrane subunit gp41, such as T20 (enfuvirtide), can bind to the N-terminal heptad repeat (NHR) of gp41 and block six-helix …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Similar Documents

Publication Publication Date Title
González Vpu protein: The viroporin encoded by HIV-1
Yu et al. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket
Kim et al. The impact on infectivity and neutralization efficiency of SARS-CoV-2 lineage B. 1.351 pseudovirus
Xing et al. A five-helix-based SARS-CoV-2 fusion inhibitor targeting heptad repeat 2 domain against SARS-CoV-2 and its variants of concern
Anand et al. Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins
Neerukonda et al. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity
Su et al. A peptide-based HIV-1 fusion inhibitor with two tail-anchors and palmitic acid exhibits substantially improved in vitro and ex vivo anti-HIV-1 activity and prolonged in vivo half-life
Wang et al. Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD
Szeto et al. Molecular basis of a dominant SARS-CoV-2 spike-derived epitope presented by HLA-A* 02: 01 recognised by a public TCR
Su et al. Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile
Willard et al. Identification of residues in Lassa virus glycoprotein subunit 2 that are critical for protein function
Trinité et al. Previous SARS-CoV-2 infection increases B. 1.1. 7 cross-neutralization by vaccinated individuals
Wang et al. Long-acting HIV-1 fusion inhibitory peptides and their mechanisms of action
Dingens et al. Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtide
Strobelt et al. SARS-CoV-2 omicron specific mutations affecting infectivity, fusogenicity, and partial TMPRSS2-independency
Peter et al. Characterization of SARS-CoV-2 escape mutants to a pair of neutralizing antibodies targeting the RBD and the NTD
Matsuura et al. Three YXXL sequences of a bovine leukemia virus transmembrane protein are independently required for fusion activity by controlling expression on the cell membrane
Friedrich et al. Glutamic acid residues in HIV-1 p6 regulate virus budding and membrane association of Gag
Beaudoin-Bussières et al. Elicitation of cluster A and Co-receptor binding site antibodies are required to eliminate HIV-1 infected cells
Dabbagh et al. Identification of the SHREK family of proteins as broad-spectrum host antiviral factors
Trinh et al. Humoral response to the HIV-1 envelope V2 region in a Thai early acute infection cohort
Roop et al. Identification of HIV-1 envelope mutations that enhance entry using macaque CD4 and CCR5
Nguyen et al. SARS-cov-2 spike-derived peptides presented by HLA molecules
Wang et al. Synergistic effect by combining a gp120-binding protein and a gp41-binding antibody to inactivate HIV-1 virions and inhibit HIV-1 infection
Seesuay et al. Human transbodies to reverse transcriptase connection subdomain of HIV-1 gag-pol polyprotein reduce infectiousness of the virus progeny